The U.S. Food and Drug Administration (FDA) approved a supplemental application for Amjevita (adalimumab-atto) on May 20, 2025. This approval pertains to an efficacy update, as indicated by the supplemental Biologics License Application (BLA 761024 S-21).
Background
Amjevita (adalimumab-atto) is a pharmaceutical product containing adalimumab, developed by Amgen Inc. This supplemental approval specifically addresses an aspect of its efficacy profile.
What this means
This supplemental efficacy approval for Amjevita (adalimumab-atto) signifies an update or expansion related to the drug's demonstrated effectiveness. Such approvals are granted by the FDA after reviewing new data that supports the drug's use. While the specific details of the efficacy update, such as a new indication, an expanded patient population, or a refinement of dosing or administration based on new efficacy data, are not detailed in this public record, the approval indicates the FDA's continued assessment and validation of Amjevita's therapeutic profile. For healthcare professionals, researchers, and patient advocates, this development confirms the ongoing regulatory oversight and potential for evolving treatment guidelines related to Amjevita. It underscores the importance of consulting the updated prescribing information for the latest approved uses and efficacy data.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). The approval for Amjevita (adalimumab-atto) was recorded on May 20, 2025, as a supplemental Biologics License Application (BLA 761024 S-21) for efficacy. Further details are available on accessdata.fda.gov.